Christine M Coquery

US Patent:

20120308578, Dec 6, 2012

Filed:

Jun 6, 2012

Appl. No.:

13/489851

Inventors:

SangKon Oh - Baltimore MD, US
Maria Virginia Pascual - Dallas TX, US
Jacques F. Banchereau - Montclair NJ, US
Christine Morel Coquery - Zion Crossroads VA, US
HyeMee Joo - Dallas TX, US

Assignee:

BAYLOR RESEARCH INSTITUTE - Dallas TX

International Classification:

G01N 33/566
A61P 19/04
G01N 21/64
A61K 39/395
C12Q 1/68
G01N 27/62

US Classification:

4241581, 435 611, 436501, 435 721, 435 612, 435 61, 4241301

Abstract:

The present invention provides a method for treating a patient at risk for or diagnosed systemic lupus erythematosus (SLE) by determining the overall expression of syndecan-1 in one or more cells of a patient suspected of having SLE; and predicting the efficacy of a therapy with a pharmaceutical agent for treating the patient, wherein a decrease in the overall expression of syndecan-1 in the patient cells when compared to the expression of syndecan-1 in normal cells indicates a predisposition to responsiveness to anti-neoplastic agent therapy, wherein the therapy comprises administering an effective amount of the pharmaceutical agent to the patient.